ALZN (Alzamend Neuro) Total Stockholders Equity: $0.73 Mil (As of Apr. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ALZN Alzamend Neuro Inc ALZN
21 GF Score
Price $1.56
! 1 Warning Sign
View Full Analysis

What is Alzamend Neuro Total Stockholders Equity?

Alzamend Neuro ALZN -4.29% 21 Total Stockholders Equity is $0.73 Mil as of Apr. 2026. GuruFocus rates ALZN with a GF Score™ of 21/100. The stock has 1 warning sign investors should review.

Alzamend Neuro's Total Stockholders Equity for the quarter that ended in Apr. 2026 was $0.73 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Alzamend Neuro's Book Value per Share for the quarter that ended in Apr. 2026 was $0.17. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Alzamend Neuro's Debt-to-Equity for the quarter that ended in Apr. 2026 was 0.00.

Alzamend Neuro  (NAS:ALZN) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Alzamend Neuro's Book Value per Share for the quarter that ended in Apr. 2026 is

Book Value per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(0.733-0)/4.256
=0.17

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Alzamend Neuro's Debt-to-Equity for the quarter that ended in Apr. 2026 is

Debt-to-Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0 + 0) / 0.733
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alzamend Neuro Total Stockholders Equity Related Terms

Alzamend Neuro Total Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Alzamend Neuro's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alzamend Neuro Total Stockholders Equity Chart

Alzamend Neuro Annual Data
Trend Apr19 Apr20 Apr21 Apr22 Apr23 Apr24 Apr25 Apr26
Total Stockholders Equity
Get a 7-Day Free Trial 13.35 3.05 -2.59 3.97 0.73

Alzamend Neuro Quarterly Data
Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26 Apr26
Total Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.97 5.34 4.37 2.19 0.73
ALZN
21GF Score
Alzamend Neuro Inc ALZN
Total Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Total Stockholders Equity of $0.73 Mil mean?
Alzamend Neuro (ALZN) has a Total Stockholders Equity of $0.73 Mil as of Apr. 2026. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Alzamend Neuro and its competitors.
Is Alzamend Neuro's Total Stockholders Equity too high?
Alzamend Neuro's current Total Stockholders Equity is $0.73 Mil. Overall, Alzamend Neuro has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Alzamend Neuro's Total Stockholders Equity compare to SILO and BGMS?
Alzamend Neuro's Total Stockholders Equity of $0.73 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Stockholders Equity for a Biotechnology company?
A good Total Stockholders Equity depends on the Biotechnology industry context. However, Total Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Stockholders Equity mean?
A high Total Stockholders Equity can signal that a stock is expensive relative to its fundamentals. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Alzamend Neuro and its competitors. Alzamend Neuro's current Total Stockholders Equity is $0.73 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alzamend Neuro stock overvalued right now?
Alzamend Neuro (ALZN) has a current Total Stockholders Equity of $0.73 Mil. The current Total Stockholders Equity is $0.73 Mil. Alzamend Neuro's overall GF Score™ is 21/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Stockholders Equity calculated?
Total Stockholders Equity is calculated from a company's financial statements. For Alzamend Neuro (ALZN), the current Total Stockholders Equity is $0.73 Mil as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Alzamend Neuro Business Description

Address 3480 Peachtree Road NE, Second Floor Suite 103, Atlanta, GA, USA, 30326
Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Its mission is to develop and market safe and effective treatments. The company's pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's.
21GF Score

Get the complete analysis for ALZN

Total Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.56
Price